PRODUCT LITERATURE

Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Healthy Children Aged 12 to 15 Months: A Phase III, Randomized, Double-Blind, Active-Controlled Clinical Trial

---

The varicella vaccine (VarV) produced by Sinovac (Dalian) obtained World Health Organization (WHO) prequalification in November 2022. However, no direct
comparative studies have been conducted between VarV and other WHO-prequalified varicella vaccines. The study aimed to assess the immunogenicity and safety of Sinovac’s VarV compared with Merck Sharp & Dohme’s (MSD) VARIVAX® (Moorgate, London, UK) following a single dose administration

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

LITERATURE

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Provarix
Varicella Vaccine

Specific Detail Info

Vaccines 2025, 13, 973

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment